Get the Stockscreener App
4.03
2.81%
0.11
After Hours:
4.00
-0.03
-0.74%
Indaptus Therapeutics Inc stock is traded at $4.03, with a volume of 140.84K.
It is up +2.81% in the last 24 hours and up +56.20% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$3.92
Open:
$3.95
24h Volume:
140.84K
Relative Volume:
0.29
Market Cap:
$4.46M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-2.1902
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
+26.33%
1M Performance:
+56.20%
6M Performance:
+739.58%
1Y Performance:
+217.32%
1-Day Range:
$3.94
$4.40
1-Week Range:
$2.86
$5.25
52-Week Range:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
4.03 | 4.34M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Why Indaptus Therapeutics Inc. stock could see breakout soon2025 Analyst Calls & Detailed Earnings Play Strategies - newser.com
Can a trend reversal in Indaptus Therapeutics Inc. lead to recoveryProfit Target & Fast Moving Trade Plans - newser.com
How moving averages guide Indaptus Therapeutics Inc. tradingMarket Trend Review & Fast Exit Strategy with Risk Control - newser.com
Top chart patterns to watch in Indaptus Therapeutics Inc.July 2025 Intraday Action & Long-Term Safe Investment Plans - newser.com
Why Indaptus Therapeutics Inc. stock is a value investor pickEarnings Growth Report & Risk Adjusted Buy/Sell Alerts - newser.com
Should you wait for a breakout in Indaptus Therapeutics Inc.Product Launch & Low Risk Investment Opportunities - newser.com
Indaptus Therapeutics Inc. stock daily chart insights2025 Retail Activity & Target Return Focused Stock Picks - newser.com
How Indaptus Therapeutics Inc. stock compares to growth peersJuly 2025 Market Mood & Daily Oversold Stock Bounce Ideas - newser.com
Can technical indicators confirm Indaptus Therapeutics Inc.’s reversal2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Indaptus Therapeutics Inc. recovery potential after sell offMarket Performance Recap & Long-Term Safe Return Strategies - newser.com
Is Indaptus Therapeutics Inc. stock positioned for digital transformationPortfolio Growth Summary & Fast Gaining Stock Reports - newser.com
How institutional ownership impacts Indaptus Therapeutics Inc. stockTrade Exit Summary & Proven Capital Preservation Tips - newser.com
What’s next for Indaptus Therapeutics Inc. stock priceWeekly Trade Review & Daily Chart Pattern Signal Reports - newser.com
What drives Indaptus Therapeutics Inc stock priceTrading Volume Surges & Free Smart Trading Classes - earlytimes.in
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):